2157.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 16:08):

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China...

Stats
今日成交量	9.66M
平均成交量	1.68M
市值	9.15B
EPS	HKD0 ( 2023-08-25 )
下一个收益日期	( HKD0 ) 2024-06-14
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-570.00
ATR14	HKD0.0290 (0.51%)

音量相关性

長: -0.04 (neutral)

短: -0.97 (very strong negative)

Signal:(37.656) Neutral

Lepu Biopharma Co., Ltd. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Lepu Biopharma Co., Ltd. 相关性 - 货币/商品

0.12
( neutral )

0.59
( weak )

0.00
( neutral )

-0.22
( neutral )

0.44
( neutral )

0.58
( weak )

Lepu Biopharma Co., Ltd. 财务报表

Annual	2023
营收:	HKD225.35M
毛利润:	HKD197.08M (87.45 %)
EPS:	HKD-0.0133

FY	2023
营收:	HKD225.35M
毛利润:	HKD197.08M (87.45 %)
EPS:	HKD-0.0133

FY	2022
营收:	HKD15.57M
毛利润:	HKD13.57M (87.12 %)
EPS:	HKD-0.420

Financial Reports:

No articles found.

Lepu Biopharma Co., Ltd.

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.